Physician profile
Jonathan E Shoag
NPI 1801162292
$1,171.87
in general payments reported to CMS, 2019-2025
15 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.75 · 2023: $280 · 2024: $193 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.13 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $276.61 | 2025 | Erleada, Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $219.01 | 2023-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Biotissue Holdings INC. | $123.90 | 2023 | |
| Ferring Pharmaceuticals INC. | $115.92 | 2024-2025 | Adstiladrin |
| Boston Scientific Corporation | $111.70 | 2022-2024 | Rezum Generator, Spaceoar Vue System - 10ml |
| Immunitybio, INC. | $74.67 | 2025 | |
| Urogen Pharma, INC. | $42.64 | 2025 | |
| Olympus America INC. | $42.07 | 2025 | Itind System |
| Dendreon Pharmaceuticals LLC | $35.89 | 2025 | Provenge |
| Photocure INC | $30.07 | 2023-2024 | Cysview |
| Teleflex LLC | $26.44 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.29 | 2025 | Lynparza |
| Verity Pharmaceuticals INC. | $20.53 | 2025 | Trelstar |
| Sumitomo Pharma America, INC. | $15.33 | 2024 | Gemtesa |
| Blue Earth Diagnostics | $12.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Shoag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.